Adding evorpacept to treatment with trastuzumab, ramucirumab, and paclitaxel may improve outcomes in HER2-positive gastric/GEJ cancer.

Abstract: Colorectal cancer (CRC) is a multifaceted disease, but it can be effectively prevented through colonoscopy for the detection of polyps. In clinical practice, the development of automatic ...

Nivolumab alone and in combination therapy improved overall and progression-free survival rates in patients with advanced gastric and gastroesophageal junction cancer; however, the risk for adverse ...

Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for ...

Satricabtagene autoleucel is under clinical development by CARsgen Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs ...

“Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver ...

silkwayrain/Getty Images New research suggests that biological age — a measure of the body’s physiological state — could predict who is at higher risk for developing colon polyps ...

What is a 5-year relative survival rate? Where do these numbers come from? 5-year relative survival rates for esophageal cancer Understanding the numbers Keep in mind that survival rates are estimates ...

The gastro oesophageal junction is where your oesophagus joins your stomach. Cancer that starts here is called gastro oesophageal junction (GOJ) cancer. It might also be called oesophago gastric ...